Fig. 2

Treatment with NPT100-18A reduces MitoSOX fluorescence intensities (FIs) and, at higher dose, increases ATP luciferase signals. (A-C) Relative levels depicted as fold changes from the respective vehicle control ± SD of n wells from N independent differentiations. (A) Treatment with 10 nM NPT100-18A had no significant effect on CellRox FIs in patient- and control-derived mDANs. CellRox FI was quantified and depicted analogously to (Fig. 1B) with dots representing well means (n ≥ 8, N ≥ 2). (B) Treatment with 10 nM NPT100-18A significantly reduced MitoSOX FIs in patient-derived but not in control mDANs (n ≥ 8, N ≥ 2). (C) Treatment with 1 µM NPT100-18A significantly increased ATP-related luciferase signals in patient- and control-derived mDANs (n ≥ 3, N ≥ 2). (A-C) Student’s t-test for comparison of DMSO- and NPT100-18A-treated control neurons and nested t-test for comparison of DMSO- and NPT100-18A-treated patient lines, ns = not significant, *P < 0.05, **P < 0.01